These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31447677)

  • 1. Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical Trials.
    Zeng LF; Pan BQ; Liang GH; Luo MH; Cao Y; Guo D; Chen HY; Pan JK; Huang HT; Liu Q; Guan ZT; Han YH; Zhao D; Zhao JL; Hou SR; Wu M; Lin JT; Li JH; Liang WX; Ou AH; Wang Q; Yang WY; Liu J
    Front Pharmacol; 2019; 10():882. PubMed ID: 31447677
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.
    Nayak S; Greenspan SL
    J Am Geriatr Soc; 2017 Mar; 65(3):490-495. PubMed ID: 28304090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
    Zhou J; Ma X; Wang T; Zhai S
    Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
    Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
    Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Viswanathan M; Reddy S; Berkman N; Cullen K; Middleton JC; Nicholson WK; Kahwati LC
    JAMA; 2018 Jun; 319(24):2532-2551. PubMed ID: 29946734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
    Li P; Wu X; Li Y; Huang J
    Clin Invest Med; 2022 Sep; 45(3):E14-22. PubMed ID: 36149052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
    Stevenson M; Davis S; Lloyd-Jones M; Beverley C
    Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials.
    Jin YZ; Lee JH; Xu B; Cho M
    BMC Musculoskelet Disord; 2019 Aug; 20(1):399. PubMed ID: 31472671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
    Boonen S; Laan RF; Barton IP; Watts NB
    Osteoporos Int; 2005 Oct; 16(10):1291-8. PubMed ID: 15986101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
    Watts NB; Worley K; Solis A; Doyle J; Sheer R
    J Manag Care Pharm; 2004; 10(2):142-51. PubMed ID: 15032563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
    Cranney A; Wells G; Willan A; Griffith L; Zytaruk N; Robinson V; Black D; Adachi J; Shea B; Tugwell P; Guyatt G;
    Endocr Rev; 2002 Aug; 23(4):508-16. PubMed ID: 12202465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of primary osteoporosis in men.
    Giusti A; Bianchi G
    Clin Interv Aging; 2015; 10():105-15. PubMed ID: 25565793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis.
    Liu M; Guo L; Pei Y; Li N; Jin M; Ma L; Liu Y; Sun B; Li C
    Int J Clin Exp Med; 2015; 8(3):3855-61. PubMed ID: 26064284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
    Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
    Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.